PAST BIOTEXAS CAFES

In partnership with Texas Association of Manufacturers (TAM), Tom Kowalski, President and CEO of THBI, Tony Bennett, President and CEO of TAM, and our member companies provide an update on COVID-19 vaccines and therapeutics and how companies produce and distribute these products.

Special guests include: David Hering, Vice President of Vaccines for North America at Pfizer for an update on their COVID-19 vaccine that is currently in phase 3 trials, and his insights on how biopharmaceutical companies prepare for the distribution of a new vaccine during a pandemic; and Tomas Cihlar, Vice President of Biology at Gilead. Gilead's antiviral medication Remdesivir is also in phase 3 trials, and received emergency use authorization use in the U.S. for the treatment of hospitalized patients with severe COVID-19.